Liver cancer/Hepatocellular Carcinoma (HCC) is a leading cause of cancer death and
represents an important cause of mortality worldwide. Several biomarkers are overexpressed in
liver cancer, such as Glypican 3 (GPC3) and Epidermal Growth Factor Receptor (EGFR). These
biomarkers play important roles in the progression of tumors and could serve as imaging and therapeutic
targets for this disease. Peptides with adequate stability, receptor binding properties, and
biokinetic behavior have been intensively studied for liver cancer imaging. A great variety of them
have been radiolabeled with clinically relevant radionuclides for liver cancer diagnosis, and many
are promising imaging and therapeutic candidates for clinical translation. Herein, we summarize the
advancement of radiolabeled peptides for the targeted imaging of liver cancer.
